Global Biotechnology Insights
Jun 16, 2017
Nanoparticles breathe new life into doxorubicin cancer treatment
Doxorubicin, originally daunorubicin, is the result of a simultaneous discovery event in the 1950's between researchers in France and Italy. The molecule, a well-known anti-cancer drug used for a variety of indications ranging from acute lymphocytic leukemia to breast cancer, was approved for use in the United States in 1974.